Emerging agents and regimens for polycythemia vera and essential thrombocythemia
Shallis RM, Podoltsev NA. Emerging agents and regimens for polycythemia vera and essential thrombocythemia. Biomarker Research 2021, 9: 40. PMID: 34049597, PMCID: PMC8161993, DOI: 10.1186/s40364-021-00298-5.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsPolycythemia veraEssential thrombocythemiaPV/ETDisease progression controlEarly efficacy signalsThrombotic risk reductionOutcomes of patientsPhase 1/2 trialNew JAK inhibitorsRed blood cell precursorsJAK-STAT pathway activationBlood cell precursorsHepcidin mimeticsTherapeutic phlebotomyDisease courseSymptom burdenEfficacy signalsHematologic parametersNovel agentsNew agentsJAK inhibitorsET pathogenesisProgression controlPatientsPathway activation